Peptide PT-141 (Bremelanotide) Injectable & Oral Treatment Protocol

Category Name	Content
Name	Peptide PT-141 (Bremelanotide) – Injectable & Oral
Uses	Peptide therapy used for enhancing sexual arousal and function, particularly in individuals with hypoactive sexual desire disorder (HSDD).
Route Of Administration	Subcutaneous injection or oral troche.
Frequency Of Use	Typically administered on an as-needed basis, at least 45 minutes prior to sexual activity. Not recommended for daily use.
Concentration(s)	Common formulations: - **Injectable:** 10 mg/mL reconstituted solution - **Oral Troche:** 0.5-1.75 mg per troche
Maximum Dosage (Day, Wk)	Recommended maximum dose: - **Injectable:** 1.75 mg subcutaneous per dose, not more than 2 doses per week - **Oral:** 0.5-1.75 mg per dose, not more than 3 doses per week
Contraindications	Pregnancy, breastfeeding, uncontrolled hypertension, cardiovascular disease, history of melanoma or skin cancer, and known hypersensitivity to Bremelanotide.
Possible Side Effects	Nausea, flushing, headache, increased blood pressure, darkening of moles or freckles, injection site reactions, or temporary fatigue.
Compatibility With Other Treatments/Drugs	Avoid concurrent use with other medications that significantly increase blood pressure. Safe to combine with testosterone therapy if prescribed appropriately.
Allergies	Assess for hypersensitivity to PT-141 or any excipients in injectable or oral formulations.
Administration Time	Injectable: Administer subcutaneously 45-60 minutes before sexual activity. Oral: Dissolve troche under the tongue 30-45 minutes before sexual activity.
Dosing/Settings	Standard dosing protocol: - **Injectable:** 1.0-1.75 mg subcutaneously as needed, max 2 doses per week. - **Oral:** 0.5-1.75 mg per troche, max 3 doses per week.
Test Spot Requirement	Not required; however, first-time users should start with the lowest effective dose to assess tolerance.
Pre-Treatment Guidelines	- Avoid alcohol and excessive fatty meals before administration to prevent nausea. - Monitor blood pressure regularly, particularly in patients with cardiovascular risk factors. - Store injectable PT-141 in the refrigerator after reconstitution.
Provider Clearance Guidelines	- Ensure the patient meets all clearance criteria before treatment. - If the patient has a history of cardiovascular issues, consider consultation with a cardiologist before prescribing. - Document all clearance decisions in the patient’s medical record.
Pre-Treatment Screening Workflow	- Does the patient have a history of uncontrolled hypertension? (If YES, contraindicated) - Has the patient had a recent cardiovascular event? (If YES, avoid treatment) - Is the patient currently pregnant or breastfeeding? (If YES, contraindicated) - Does the patient have a history of melanoma or abnormal skin pigmentation? (If YES, use with caution)
What To Do If Adverse Reaction Occurs	- **Severe nausea**: Recommend anti-nausea medication (e.g., ondansetron 4 mg). - **Hypertension (BP >160/100)**: Discontinue PT-141 and monitor blood pressure. - **Injection site reactions**: Apply a cool compress and monitor for signs of infection. - **Persistent headache or flushing**: Lower the dosage in future administrations.
Clinic Implementation Guidelines	- Confirm all consents are signed before treatment. - Educate the patient on proper injection technique or oral troche usage. - Store injectable PT-141 per compounding pharmacy recommendations. - Schedule follow-up to assess efficacy and tolerance.
Photographic Documentation Protocol	Not required for PT-141 administration.
Post-Treatment Care	- Monitor for side effects and adjust dosing as needed. - Maintain a record of patient response to therapy. - Encourage hydration and blood pressure monitoring in hypertensive patients.
Additional Documentation Requirements	- Signed informed consent detailing risks, benefits, and expected outcomes. - Treatment log including prescribed dosage and patient response. - Post-treatment care instructions provided and documented.